Quantum-Si Announces Commercial Availability of Platinum™, the World’s First Next-Generation Single-Molecule Protein Sequencing Platform
Company Appoints Life Science Veteran
- The accessibility gained when using Platinum™ is expected to transform science and understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of next-generation DNA sequencing revolutionized our knowledge of the human genome over the past two decades.
- The elegant simplicity of this next-generation protein sequencing platform enables broad-scale access to proteomic data, positioning Platinum™ as a critical instrument for the future of proteomics research.
- The world’s first proven protein sequencing technology is available immediately for ordering with shipments beginning in Q1 2023.
Grace Johnston, PhD, has been appointed as the Company’s Chief Commercial Officer to lead global sales and commercial activities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005214/en/
Quantum-Si Appoints Life Science Veteran
The launch of Platinum marks Quantum-Si’s movement out of almost a decade of stealth innovation. The Company was founded in 2013 by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation recipient Dr.
“Next-generation protein sequencing represents the vanguard of new therapeutic discovery, however, no other company has met the promise of delivering an accessible single-molecule protein sequencing platform – until today,” said
Before today, proteomics technology has been hindered by its use of large expensive machinery, technically challenging and time-consuming protocols, and a lack of custom probes that can reliably distinguish between amino acids, much less those with post translational modifications. In contrast, Quantum-Si’s next-generation sequencing system leverages Time Domain Sequencing™ technology which alleviates this hurdle by monitoring for amino-acid specific patterns in fluorescent probe behavior. This means that a single probe can be used for the robust identification of multiple distinct amino acids, including those containing post translational modifications. This approach provides a sensitive scalability that eliminates roadblocks of complex chemistry and large, expensive equipment utilized by other technologies, while providing the sensitivity, scalability, and accessibility needed to accelerate biomedical research.
“We learned from the success of next-generation DNA sequencing how to move beyond big machines, expensive facilities and the need for significant training, and we saw the benefits of placing the power of sequencing into the hands of individual researchers,” said Dr.
The Company also announced it has appointed
"With Platinum’s advanced capabilities and innovative technology, customers will be able to uncover new insights within the proteome and make breakthrough therapeutic discoveries that were previously impossible,” said
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on